Evidence map›Paper›PMID 20200425›Full record

ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2010

PTGER2 overexpression in colorectal cancer is associated with microsatellite instability, independent of CpG island methylator phenotype.

Yoshifumi Baba, Katsuhiko Nosho, Kaori Shima, Wolfram Goessling, Andrew T Chan, Kimmie Ng, Jennifer A Chan, Edward L Giovannucci, Charles S Fuchs, Shuji Ogino

Open access · bronzeAbstract read
In one paragraph

Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 44 citations in OpenAlex.

  1. Article
  2. Prostaglandin ENature communications · 2024
    Article
  3. Review
  4. Development of anMolecular therapy. Methods & clinical development · 2023
    Article
  5. Article
  6. Article
  7. Frontiers in cell and developmental biology · 2023
    Article
  8. The COX-2-PGE2 Pathway Promotes Tumor Evasion in Colorectal Adenomas.Cancer prevention research (Philadelphia, Pa.) · 2022
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Familial colorectal cancer type X: genetic profiles and phenotypic features.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2015
    Review
  15. Article
  16. Article
  17. Review
  18. Molecular pathological epidemiology of epigenetics: emerging integrative science to analyze environment, host, and disease.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2013
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Yoshifumi BabaDepartment of Medical Oncology, Dana-FarberCancer Institute and Harvard Medical School, Boston, Massachusetts, USA.
Katsuhiko Nosho
Kaori Shima
Wolfram Goessling
Andrew T Chan
Kimmie Ng
Jennifer A Chan
Edward L Giovannucci
Charles S Fuchs
Shuji Ogino
Massachusetts General Hospital · USBrigham and Women's Hospital · USDana-Farber Cancer Institute · US

Funding

Statistical MethodsP01CA087969 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI TWOROGER, SHELLEY S · 2000 to 2019
$77.8M
Validity of Diet and Activity Measures in WomenP01CA055075 · NCI · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI WILLETT, WALTER C. · 1991 to 2009
$41.8M
Tissue and Pathology ResourcesP50CA127003 · NCI · DANA-FARBER CANCER INST · PI EL-BARDEESY, NABEEL, SELLERS, WILLIAM R · 2007 to 2023
$33.2M
Inflammation and Colorectal NeoplasiaR01CA137178 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI CHAN, ANDREW T · 2009 to 2019
$6.5M
Prospective Studies of Colorectal AdenomaK07CA107412 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI CHAN, ANDREW T · 2005 to 2009
$800k
Molecular Epidemiology of Colorectal CancerK07CA122826 · NCI · DANA-FARBER CANCER INST · PI OGINO, SHUJI · 2007 to 2010
$634k
NCI NIH HHS K07 CA107412NCI NIH HHS K07 CA122826NCI NIH HHS P01 CA055075NCI NIH HHS P01 CA087969NCI NIH HHS P01 CA55075NCI NIH HHS P01 CA87969NCI NIH HHS P50 CA127003NCI NIH HHS R01 CA137178
6 · The paper itself

Abstract

backgroundProstaglandin-endoperoxide synthase 2 (PTGS2, the HUGO Gene Nomenclature Committee-approved official symbol for cycloxygenase-2, COX-2) and its enzymatic product prostaglandin E2 have critical roles in inflammation and carcinogenesis through the G protein-coupled receptor PTGER2 (EP2). The PTGS2 (COX-2) pathway is a promising target for cancer therapy and chemoprevention. PTGS2 (COX-2) expression in colon cancer has been inversely associated with survival as well as tumoral microsatellite instability (MSI) and the CpG island methylator phenotype (CIMP). However, the prognostic significance of PTGER2 expression or its relationship with MSI, CIMP, LINE-1 hypomethylation, or PTGS2 (COX-2) remains uncertain.

methodsUsing the database of 516 colorectal cancers in two prospective cohort studies with clinical outcome data, we detected PTGER2 overexpression in 169 (33%) tumors by immunohistochemistry. We analyzed MSI using 10 microsatellite markers; CIMP by MethyLight (real-time methylation-specific PCR) on an eight-marker panel [CACNA1G, CDKN2A (p16), CRABP1, IGF2, MLH1, NEUROG1, RUNX3 and SOCS1]; BRAF, KRAS, PIK3CA, and methylation in LINE-1 by Pyrosequencing; and CTNNB1 (beta-catenin) and TP53 (p53) by immunohistochemistry.

resultsPTGER2 overexpression was positively associated with the mucinous component (P = 0.0016), signet ring cells (P = 0.0024), CIMP-high (P = 0.0023), and MSI-high (P < 0.0001). In multivariate analysis, the significant relationship between PTGER2 and MSI-high persisted (adjusted odds ratio, 2.82; 95% confidence interval, 1.69-4.72; P < 0.0001). PTGER2 was not significantly associated with PTGS2 (COX-2), TP53, or CTNNB1 expression, patient survival, or prognosis.

conclusionPTGER2 overexpression is associated with MSI-high in colorectal cancer. IMPACT: Our data imply potential roles of inflammatory reaction by PTGER2 upregulation in carcinogenic process to MSI-high colorectal cancer.

Indexed as

Microsatellite Instabilitybeta CateninBiomarkers, TumorColorectal NeoplasmsCpG IslandsCyclooxygenase 2DNA MethylationFemaleHumansImmunohistochemistryKaplan-Meier EstimateMalePhenotypePrognosisReceptors, Prostaglandin EReceptors, Prostaglandin E, EP2 Subtypebeta CateninBiomarkers, TumorCyclooxygenase 2PTGER2 protein, humanReceptors, Prostaglandin EReceptors, Prostaglandin E, EP2 SubtypeTumor Suppressor Protein p53

Identifiers

PMID20200425
PMCPMC2837535
OpenAlexW2121233184

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.